We are live on ! Find out more

2,059 hedge funds and large institutions have $140B invested in Pfizer in 2016 Q4 according to their latest regulatory filings, with 193 funds opening new positions, 870 increasing their positions, 797 reducing their positions, and 64 closing their positions.

New
Increased
Maintained
Reduced
Closed

202% more first-time investments, than exits

New positions opened: 193 | Existing positions closed: 64

5% more funds holding

Funds holding: 1,9632,059 (+96)

9% more repeat investments, than reductions

Existing positions increased: 870 | Existing positions reduced: 797

0.04% more ownership

Funds ownership: 74.71%74.74% (+0.04%)

3% less capital invested

Capital invested by funds: $144B → $140B (-$4.35B)

17% less call options, than puts

Call options by funds: $2.07B | Put options by funds: $2.49B

26% less funds holding in top 10

Funds holding in top 10: 234172 (-62)

Holders
2,059
Holders Change
+96
Holders Change %
+4.89%
% of All Funds
51.48%
Holding in Top 10
172
Holding in Top 10 Change
-62
Holding in Top 10 Change %
-26.5%
% of All Funds
4.3%
New
193
Increased
870
Reduced
797
Closed
64
Calls
$2.07B
Puts
$2.49B
Net Calls
-$424M
Net Calls Change
-$342M
Name Holding Trade Value Shares
Change
Change in
Stake
TYCC
1026
Texas Yale Capital Corp
Florida
$2.73M +$1.73M +56,531 +176%
NONA
1027
Ninety One North America
New York
$2.71M -$31.1K -1,018 -1%
ACPU
1028
Arrowgrass Capital Partners (US)
Delaware
$2.7M +$1.24M +40,729 +87%
GD
1029
Grandfield & Dodd
New York
$2.69M +$5.04K +165 +0.2%
LA
1030
LVW Advisors
New York
$2.68M +$54.7K +1,792 +2%
LWCFA
1031
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$2.68M +$119K +3,906 +5%
VIA
1032
Vantage Investment Advisors
Pennsylvania
$2.67M +$82.2K +2,692 +3%
FA
1033
Fagan Associates
New York
$2.66M -$5.59K -183 -0.2%
ICM
1034
Ionic Capital Management
New York
$2.65M +$2.63M +86,112 New
ST
1035
Somerset Trust
Pennsylvania
$2.65M -$132K -4,337 -5%
PFPT
1036
Pinnacle Financial Partners (Tennessee)
Tennessee
$2.65M -$158K -5,186 -6%
ACP
1037
Aviance Capital Partners
Florida
$2.61M -$587K -19,234 -19%
B
1038
BancorpSouth
Mississippi
$2.6M +$195K +6,375 +8%
BCM
1039
BlueCrest Capital Management
Jersey
$2.6M +$2.21M +72,429 +608%
RMDI
1040
R.M. Davis Inc
Maine
$2.59M -$55.3K -1,810 -2%
AIM
1041
Anchor Investment Management
South Carolina
$2.59M +$58.6K +1,918 +2%
PP
1042
Pegasus Partners
Wisconsin
$2.58M -$2.79M -91,495 -52%
HCM
1043
Howland Capital Management
Massachusetts
$2.57M +$901K +29,522 +55%
CFA
1044
Camarda Financial Advisors
Florida
$2.57M -$102K -3,342 -4%
Aristotle Capital Management
1045
Aristotle Capital Management
California
$2.56M
ANRIA
1046
American National Registered Investment Advisor
Texas
$2.56M
ST
1047
Spinnaker Trust
Maine
$2.56M -$210K -6,876 -8%
TCOT
1048
Trust Company of Toledo
Ohio
$2.56M +$30.3K +992 +1%
BE
1049
Bonness Enterprises
District of Columbia
$2.55M -$161K -5,270 -6%
AMM
1050
American Money Management
California
$2.55M -$135K -4,427 -5%

PFE Hedge Fund Activity: Q4 2016 in Review

2,059 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2016, worth a combined $140B — down 3% from $144B a quarter earlier.

Buyers outnumbered sellers: 193 funds opened new PFE positions and 64 closed out — a net gain of 129 holders — while 870 added to existing stakes and 797 trimmed.

The largest buyer was Boston Partners, adding an estimated $550M. The largest seller was Capital World Investors, cutting an estimated $1.63B.

  • 2,059 institutional investors held Pfizer (PFE) as of Q4 2016, up from 1,963 in Q3 2016.
  • Funds reported $140B of Pfizer stock for Q4 2016, down 3% quarter-over-quarter.
  • 193 funds opened new Pfizer positions in Q4 2016 and 64 closed out, a net change of +129 holders.
  • The largest Pfizer buyer in Q4 2016 was Boston Partners, an estimated $550M added.
  • The largest Pfizer seller in Q4 2016 was Capital World Investors, an estimated $1.63B sold.

Based on aggregated 13F filings for Q4 2016.